Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

BACKGROUND: Combining bevacizumab and chemotherapy produced superior response rates compared with chemotherapy alone in metastatic breast cancer. As bevacizumab may cause hypertension (HTN) and increase the risk of cardiac failure, we performed a pilot study to evaluate the feasibility and toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gullo, Giuseppe, J. Eustace, Alex, Canonici, Alexandra, M. Collins, Denis, Kennedy, Michael J., Grogan, Liam, Breathhnach, Oscar, McCaffrey, John, Keane, Maccon, Martin, Michael J., Gupta, Rajnish, Leonard, Gregory, O’Connor, Miriam, Calvert, Paula M., Donnellan, Paul, Walshe, Janice, McDermott, Enda, Scott, Kathleen, Hernando, Andres, Parker, Imelda, W. Murray, David, C. O’Farrell, Alice, Maratha, Ashwini, Dicker, Patrick, Rafferty, Mairin, Murphy, Verena, O’Donovan, Norma, M. Gallagher, William, Ky, Bonnie, Tryfonopoulos, Dimitrios, Moulton, Brian, T. Byrne, Annette, Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657121/
https://www.ncbi.nlm.nih.gov/pubmed/31384312
http://dx.doi.org/10.1177/1758835919864236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657121/
https://www.ncbi.nlm.nih.gov/pubmed/31384312
http://dx.doi.org/10.1177/1758835919864236

Ejemplares similares